Neonatal Med Search


Neonatal Med > Volume 24(1); 2017 > Article
Neonatal Medicine 2017;24(1):1-6.
DOI:    Published online February 28, 2017.
Bronchopulmonary Dysplasia and Ureaplasma: What Do We Know So Far?.
Nicole de la Haye, Matthias C Hütten, Steffen Kunzmann, Boris W Kramer
1Department of Pediatrics, Maastricht University Medical Center (MUMC), Maastricht, The Netherlands.
2School of Oncology and Developmental Biology (GROW), Maastricht, The Netherlands.
3Division of Neonatology, Department of Pediatrics, Würzburg University Hospital, Würzburg, Germany.
4School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
5Department of Neonatology and Pediatric Intensive Care Medicine, Bürgerhospital Frankfurt am Main, Germany.
Bronchopulmonary dysplasia (BPD) is the most common morbidity of prematurity. BPD is a chronic respiratory disease related to lung-injury during the primary course of critical lung disease such as respiratory distress syndrome or when abnormal development of the preterm lung occurs. Abnormal lung development not only results from primary lung injury in the first days after birth, but also secondary injury through abnormal repair resulting in arrested and abnormal alveolarization, fibrosis and pulmonary vascular dysgenesis. Chorioamnionitis is a risk factor that plays an important role in the development of BPD. Ureaplasma subspecies (spp.) are the most common isolated organisms from chorioamniotic tissue after premature births. Therefore Ureaplasma spp. appear to play an important role in the development of BPD, and treatment or prophylactic treatment of these infections or colonization may reduce the incidence, morbidity and mortality of BPD. Ureaplasma spp. infections are challenging not only to treat, but also to diagnosis in a timely manner. This review summarizes the current state of treatment and new developments in the treatment of Ureaplasma exposure in premature infants.
Key Words: Bronchopulmonary dysplasia; Ureaplasma; Chorioamnionitis; ultrasonography; Solithromycin; Azithromycin


Browse all articles >

Editorial Office
34, Sajik-ro 8–gil(King’s Gargen 3 Block 1207), Jongno-gu, Seoul 03174, Republic of Korea
Tel: +82-2-730-1993    Fax: +82-2-730-1994    E-mail:                

Copyright © 2024 by The Korean Society of Neonatology.

Developed in M2PI

Close layer
prev next